Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan-based bismuth quadruple therapy for Helicobacter pylori: 10-day vs 14-day
ChiCTR2400081962Phase 4Not yet recruiting
- Sponsor
- Nanjing Jiangbei Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegoprazan in Helicobacter pylori infection (2 arms), sponsored by Nanjing Jiangbei Hospital. Primary endpoint: Helicobacter pylori eradication rate. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
tegoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400081962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081962.